Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop: analyst
New data support Merus' standard-of-care hopes as it moves ahead with late-stage testing. With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results